Skip to content

Study · Non-randomized trial · n = 24 · 1987

14 results

New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository.

Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Engelbeen JP, Stasse P, Hermans P, de Buisseret JP

Clinical orthopaedics and related research1 Apr 1987Cited by 14 (Europe PMC)

PMID3549096 (opens in a new tab)DOI10.1097/00003086-198704000-00008 (opens in a new tab)PepBankPUB-03549096
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Paget disease, the higher nasal salmon calcitonin dose was more effective than the lower dose on bone turnover.

    In plain wordsIn Paget disease, the higher nasal salmon calcitonin dose affected bone turnover more than the lower dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedDose comparison for bone turnover
    Study

    n = 24

    Comparator
    200 units daily nasal salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 units daily · nasal spray · one yearAs given in this study (human).

    Source sentences

    Summary
    The two regimens proved active on the parameters of bone turnover and the higher dose was more effective than the lower one.
    1 context sentence
    Summary · context
    The nasal spray was used at 200 units daily in 15 patients with Paget's disease, and at 400 units daily in another nine patients, both trials lasting one year.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Paget disease, nasal salmon calcitonin at the lower dose affected bone turnover parameters.

    In plain wordsIn Paget disease, the lower nasal salmon calcitonin dose affected bone turnover.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedBone turnover at lower nasal dose
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 units daily · nasal spray · one yearAs given in this study (human).

    Source sentences

    Summary
    The two regimens proved active on the parameters of bone turnover and the higher dose was more effective than the lower one.
    1 context sentence
    Summary · context
    The nasal spray was used at 200 units daily in 15 patients with Paget's disease, and at 400 units daily in another nine patients, both trials lasting one year.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Paget disease, salmon calcitonin suppositories significantly decreased bone turnover parameters at the third month.

    In plain wordsIn Paget disease, salmon calcitonin suppositories significantly lowered bone turnover measures at the third month.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBone turnover at third month
    Study

    n = 12

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    300 unit · suppository · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    At the third month of therapy, the parameters of bone turnover were significantly depressed.
    1 context sentence
    Summary · context
    Similarly, a 300 unit suppository was given to another 12 patients.
  4. 04HumanNon-randomized trialSafety outcome

    In Paget disease, no patient interrupted salmon calcitonin suppository therapy.

    In plain wordsIn Paget disease, no patient stopped salmon calcitonin suppository therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableSuppository therapy interruption
    Study

    n = 12

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · suppositoryAs given in this study (human).

    Source sentences

    Summary
    Only one patient interrupted the nasal spray therapy, and no one interrupted the suppository therapy.
    1 context sentence
    Summary · context
    Similarly, a 300 unit suppository was given to another 12 patients.
  5. 05HumanNon-randomized trialEfficacy outcome

    In Paget disease, nasal salmon calcitonin at the higher dose affected bone turnover parameters.

    In plain wordsIn Paget disease, the higher nasal salmon calcitonin dose affected bone turnover.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedBone turnover at higher nasal dose
    Study

    n = 9

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 units daily · nasal spray · one yearAs given in this study (human).

    Source sentences

    Summary
    The two regimens proved active on the parameters of bone turnover and the higher dose was more effective than the lower one.
    1 context sentence
    Summary · context
    The nasal spray was used at 200 units daily in 15 patients with Paget's disease, and at 400 units daily in another nine patients, both trials lasting one year.
  6. 06HumanNon-randomized trialActivity measurement

    In volunteers, nasal and suppository salmon calcitonin showed renal biological activity.

    In plain wordsIn volunteers, nasal and suppository salmon calcitonin showed activity in the kidneys.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedRenal biological activity
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · nasal spray and suppositoryAs given in this study (human).

    Source sentences

    Summary
    Both new modes of administration were found to be active on the kidney (and the suppository was found to affect bone turnover as well).
  7. 07HumanNon-randomized trialActivity measurement

    In volunteers, salmon calcitonin suppositories affected bone turnover.

    In plain wordsIn volunteers, salmon calcitonin suppositories affected bone turnover.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedBone turnover in volunteers
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · suppositoryAs given in this study (human).

    Source sentences

    Summary
    Both new modes of administration were found to be active on the kidney (and the suppository was found to affect bone turnover as well).
  8. 08HumanNon-randomized trialEfficacy outcome

    In volunteers, nasal and rectal salmon calcitonin were less effective than parenteral administration.

    In plain wordsIn volunteers, nasal and rectal salmon calcitonin were less effective than injected salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBiological effectiveness by route
    Study

    n: not reported in source

    Comparator
    Parenteral salmon calcitonin
    Outcome group
    Biological Activity · Whole body
    Studied dose
    Dose not stated · nasal and rectalAs given in this study (human).

    Source sentences

    Summary
    The parenteral route proved more effective, but the nasal and/or rectal routes were devoid of systemic side effects and had minimal local intolerance.
  9. 09HumanNon-randomized trialSafety outcome

    In volunteers, the nasal and/or rectal routes of salmon calcitonin were devoid of systemic side effects.

    In plain wordsIn volunteers, the nasal and/or rectal routes of salmon calcitonin were devoid of systemic side effects.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeSystemic side effects in volunteers
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal and rectalAs given in this study (human).

    Source sentences

    Summary
    The parenteral route proved more effective, but the nasal and/or rectal routes were devoid of systemic side effects and had minimal local intolerance.
  10. 10HumanNon-randomized trialSafety outcome

    In volunteers, nasal and rectal salmon calcitonin caused minimal local intolerance.

    In plain wordsIn volunteers, nasal and rectal salmon calcitonin caused minimal local intolerance.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableLocal intolerance in volunteers
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal and rectalAs given in this study (human).

    Source sentences

    Summary
    The parenteral route proved more effective, but the nasal and/or rectal routes were devoid of systemic side effects and had minimal local intolerance.
  11. 11HumanNon-randomized trialEfficacy outcome

    In Paget disease, nasal and suppository salmon calcitonin improved focal bone balance in osteolytic lesions on sequential roentgenograms.

    In plain wordsIn Paget disease, nasal and suppository salmon calcitonin improved local bone balance in bone lesions.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedFocal bone balance
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · nasal spray and suppositoryAs given in this study (human).

    Source sentences

    Summary
    Both new modes of therapy were able to improve the focal bone balance of the osteolytic lesions monitored on sequential roentgenograms.
  12. 12HumanNon-randomized trialSafety outcome

    In Paget disease, nasal and suppository salmon calcitonin produced no systemic side effects.

    In plain wordsIn Paget disease, nasal and suppository salmon calcitonin produced no systemic side effects.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableSystemic side effects in patients
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal spray and suppositoryAs given in this study (human).

    Source sentences

    Summary
    Systemic side effects were absent and local side effects were minimal.
  13. 13HumanNon-randomized trialSafety outcome

    In Paget disease, nasal and suppository salmon calcitonin produced minimal local side effects.

    In plain wordsIn Paget disease, nasal and suppository salmon calcitonin produced minimal local side effects.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableLocal side effects in patients
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal spray and suppositoryAs given in this study (human).

    Source sentences

    Summary
    Systemic side effects were absent and local side effects were minimal.
  14. 14HumanNon-randomized trialSafety outcome

    In Paget disease, one patient interrupted nasal salmon calcitonin therapy.

    In plain wordsIn Paget disease, one patient stopped nasal salmon calcitonin therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableNasal therapy interruption
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Therapy interruptions
    1 patient
    nasal spray

    Source sentences

    Summary
    Only one patient interrupted the nasal spray therapy, and no one interrupted the suppository therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.